FY2025 EPS Estimates for Legend Biotech Increased by Analyst

Legend Biotech Co. (NASDAQ:LEGN) – Analysts at HC Wainwright raised their FY2025 earnings per share estimates for Legend Biotech in a report released on Wednesday, October 16th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of $0.12 for the year, up from their previous estimate of $0.10. HC Wainwright has a “Buy” rating and a $73.00 price objective on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.51) per share.

Other equities analysts have also recently issued reports about the stock. BMO Capital Markets reaffirmed an “outperform” rating and set a $90.00 target price on shares of Legend Biotech in a research note on Wednesday, July 3rd. Redburn Atlantic assumed coverage on shares of Legend Biotech in a research note on Tuesday, October 8th. They set a “buy” rating and a $86.00 target price for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $86.00 target price on shares of Legend Biotech in a research note on Friday, September 27th. TD Cowen cut their target price on shares of Legend Biotech from $71.00 to $67.00 and set a “buy” rating for the company in a research note on Monday, July 15th. Finally, Scotiabank raised their target price on shares of Legend Biotech from $70.00 to $76.00 and gave the company a “sector outperform” rating in a research note on Monday, August 12th. Fourteen analysts have rated the stock with a buy rating, According to data from MarketBeat, Legend Biotech has a consensus rating of “Buy” and a consensus price target of $82.08.

Legend Biotech Stock Down 0.5 %

LEGN stock opened at $42.87 on Friday. Legend Biotech has a twelve month low of $38.60 and a twelve month high of $70.13. The company has a quick ratio of 4.78, a current ratio of 4.84 and a debt-to-equity ratio of 0.25. The stock has a market cap of $7.81 billion, a P/E ratio of -32.98 and a beta of 0.10. The business’s 50-day moving average price is $51.44 and its 200-day moving average price is $49.36.

Legend Biotech (NASDAQ:LEGN) last announced its earnings results on Friday, August 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.49. Legend Biotech had a negative return on equity of 23.20% and a negative net margin of 62.50%. The business had revenue of $186.50 million for the quarter, compared to analysts’ expectations of $125.25 million. During the same period last year, the firm posted ($0.27) earnings per share. The business’s revenue for the quarter was up 154.4% on a year-over-year basis.

Institutional Trading of Legend Biotech

Large investors have recently bought and sold shares of the stock. Blue Trust Inc. lifted its stake in Legend Biotech by 10,075.0% during the 2nd quarter. Blue Trust Inc. now owns 814 shares of the company’s stock valued at $36,000 after acquiring an additional 806 shares during the period. American International Group Inc. lifted its stake in shares of Legend Biotech by 50.0% in the 1st quarter. American International Group Inc. now owns 900 shares of the company’s stock valued at $50,000 after purchasing an additional 300 shares during the period. AM Squared Ltd acquired a new position in shares of Legend Biotech in the 2nd quarter valued at $71,000. California State Teachers Retirement System lifted its stake in shares of Legend Biotech by 196.3% in the 1st quarter. California State Teachers Retirement System now owns 3,345 shares of the company’s stock valued at $188,000 after purchasing an additional 2,216 shares during the period. Finally, BNP Paribas acquired a new position in Legend Biotech during the first quarter worth $199,000. Hedge funds and other institutional investors own 70.89% of the company’s stock.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).